Cite

HARVARD Citation

    Rugo, H. et al. (2021). PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer. Journal of the National Cancer Institute. pp. 1733-1743. [Online]. 
  
Back to record